Schott Kaisha expands its vial production capacity for Covid-19 vaccine

Schott Kaisha has announced an immediate investment of Rs 105 crore ( approximately EUR 12 million) into its existing facilities to increase its vial production by 300 million pieces. The decision comes at a time when drug manufacturers around the world are undergoing Covid-19 vaccine trials. Such complex medications are stored in Type 1 glass vials produced at Schott Kaisha plants in Gujarat and Daman. The Indo- German venture with the international technology group, Schott AG, plans to complete this production ramp-up within a record time of 12 months. A long-term investment plan and consistent infrastructure growth over the years has helped the company expand its production capabilities quickly. Over the last three years, it had invested approximately Rs 434 crore and set up two new plants in Umarsadi, Gujarat, and Baddi, Himachal Pradesh. With the recently opened facility in Umarsadi, Schott Kaisha was already manufacturing over 3 billion pieces of ampoules, vials, syringes, and cartridges annually. The company is providing vaccine vials to all the key vaccine developers in the country and manufacturers abroad.…

Choose your subscription to read more